Arotinolol hydrochloride（Arotinolol HCl） is a non-selective α/β-adrenergic receptor blocker.Arotinolol hydrochloride inhibits the binding of the radioligand 125I-ICYP to the 5HT1B-hydroxytryptamine receptor. Arotinolol hydrochloride is an antihypertensive and anti-obesity agent that improves aortic stiffness in rats and is used to study obesity-related diseases.

Arotinolol HCl shows its potency for inhibiting the binding of the same radioligand to the 5HT1B-serotonergic receptor site, Arotinolol HCl displaces 125I-ICYP binding to 5HT1B-receptors with the pKi values of 7.97 and 8.16 respectively for β1 and β2 adrenergic receptors.[3]
Arotinolol HCl shows its selectivity of β-adrenergic receptors, the result of Arotinolol HCl for β1 and β2 adrenoceptors in 125I-ICYP binding to rat cerebral cortical membranes with pKi value of 9.74 and 9.26 respectively. The selective of β1 and β2 is equal.[3]

Arotinolol HCl (200 mg/kg; oral gavage; 8 weeks) can significantly decrease central arterial pressure (CAP) and pulse wave velocity (PWV), in addition, it reduces aortic collagen depositions and finally improves arterial stiffness in SHR mice.[3]